Charles River Acquires ChanTest
News Oct 31, 2014
Headquartered in Cleveland, Ohio, ChanTest offers a panel of more than 120 validated assays to test ion channels, which we believe is the most comprehensive panel in the industry. ChanTest scientists are thought leaders in the field of ion channels and are currently working with the FDA on the Comprehensive in vitro Proarrhythmia Assay (CiPA) guidelines.
As researchers increasingly incorporate ion channel testing into their molecule design process, access to more comprehensive ion channel assay panels will be invaluable to supporting their drug discovery efforts. With this acquisition, we are emerging as the market-leading CRO in ion channel drug discovery and associated in vitro safety testing.
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019